Infinity Pharmaceuticals, Inc. (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
37 Pages - GLDATA50998
$250.00

Summary

Infinity Pharmaceuticals, Inc. (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The company’s product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals, Inc. (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Partnerships 13
Pharm-Olam International Enters into Agreement with Infinity Pharma 13
Lead Discovery Center Partners with Infinity Pharma 14
Infinity Pharma Terminates Co-Development Agreement With Mundipharma And Purdue Pharma 15
Infinity Pharma Extends Co-Development Agreement With Mundipharma 17
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International 19
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program 21
Licensing Agreements 23
AbbVie Enters into Licensing Agreement with Infinity Pharma for IPI-145 23
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 25
Infinity Pharma Enters Into License Agreement With Intellikine 27
Equity Offering 29
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 29
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 31
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 32
Infinity Pharmaceuticals, Inc. - Key Competitors 34
Key Employees 35
Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Infinity Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 13
Lead Discovery Center Partners with Infinity Pharma 14
Infinity Pharma Terminates Co-Development Agreement With Mundipharma And Purdue Pharma 15
Infinity Pharma Extends Co-Development Agreement With Mundipharma 17
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International 19
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program 21
AbbVie Enters into Licensing Agreement with Infinity Pharma for IPI-145 23
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 25
Infinity Pharma Enters Into License Agreement With Intellikine 27
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 29
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 31
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 32
Infinity Pharmaceuticals, Inc., Key Competitors 34
Infinity Pharmaceuticals, Inc., Key Employees 35
Infinity Pharmaceuticals, Inc., Subsidiaries 36

List of Figures
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Infinity Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838